Search clinical trials for: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

Total 30 results

Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

COVID-19

China
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA; ZHONGYIANKE... and other collaborators

Recruiting

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

COVID-19

China
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE...

Recruiting

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

COVID-19 | Influenza

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

Covid19

China
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

COVID-19

China
Institute of Medical Biology, Chinese Academy of...
West China Second University Hospital; Yunnan Center for Disease Control and...

Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

COVID-19

China
Institute of Medical Biology, Chinese Academy of...
West China Second University Hospital; Yunnan Center for Disease Control and...

Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

COVID-19

China
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Active, not recruiting

A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

COVID-19

China
Pontificia Universidad Catolica de Chile

Completed

Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant

COVID-19 | SARS-CoV-2 Infection | Solid Organ Transplant | Vaccine Response Impaired

Chile
Canadian Immunization Research Network
Massachusetts General Hospital; CHU de Quebec-Universite Laval; McGill University... and other collaborators

Active, not recruiting

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (MOSAIC)

COVID-19

Canada
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Covid19

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

COVID-19

United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
Collegium Medicum w Bydgoszczy

Active, not recruiting

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study (DANTE-SIRIO 7)

SARS-CoV2 Infection | SARS-CoV2 Antibodies

Poland
Collegium Medicum w Bydgoszczy

Recruiting

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation (DANTE-SIRIO 8)

SARS-CoV2 Infection | SARS-CoV2 Antibodies

Poland
Korea University Guro Hospital
Korean Center for Disease Control and Prevention

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Zhongnan Hospital

Recruiting

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

SARS-CoV-2 | Safety | Immunotoxicity

China
IRCCS Sacro Cuore Don Calabria di Negrar

Recruiting

Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups. (COVaxFragile)

COVID-19

Italy
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Pfizer

Completed

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

HEALTHY

China
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
Memorial Sloan Kettering Cancer Center
Pfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of Virginia

Completed

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Neurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial Hemangiopericytoma

United States
Memorial Sloan Kettering Cancer Center
Otsuka America Pharmaceutical; Ludwig Institute for Cancer Research

Completed

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Multiple Myeloma

United States
King's College Hospital NHS Trust
King's College London; Fight for Sight (Funder)

Recruiting

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). (TIGER)

Eye Diseases | Macular Degeneration, Wet | Sub-Macular Hemorrhage

United Kingdom
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Completed

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer | Squamous Cell Cancer

United States
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Puerto Rico
Memorial Sloan Kettering Cancer Center

Completed

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)

Non-Hodgkin's Lymphoma | CNS Lymphoma | CNS Brain Cancer

United States

Search clinical trials for: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations